Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Serotonin Syndrome × Receptor-Like Protein Tyrosine Phosphatases, Class 2 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 1 Serotonin Syndrome 1 Rectal Neoplasms 1 Malignant Carcinoid Syndrome 1 Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

telotristat ethyl 5 lanreotide 2 telotristat 1 pasireotide 1 lutetium Lu 177 dotatate 1 alpha-methyltryptophan 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Random Allocation 1 Panitumumab 1 Octreotide 1 Magnetic Resonance Spectroscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated

Malignant Carcinoid Syndrome, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡